<DOC>
	<DOCNO>NCT01964534</DOCNO>
	<brief_summary>To evaluate combination ABI-007 gemcitabine LV5FU2 .</brief_summary>
	<brief_title>Efficacy ABI-007 Plus Gemcitabine sLV5FU2 First-line Therapy Patients With Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>Gemcitabine alone triplet combination 5FU , irinotecan oxaliplatin ( FOLFIRINOX ) reference 1st line treatment metastatic pancreatic cancer . The aim AFUGEM study evaluate efficacy weekly ABI-007 combination weekly gemcitabine fortnightly simplify LV5FU2 regimen term progression-free survival patient previously untreated metastatic pancreatic cancer . ABI-007 approve commercialization 38 country , include US , Canada , EU , Australia , China , India Korea treatment woman metastatic breast cancer . ABI-007 alone combination evaluate number cancer , include metastatic melanoma , non-small cell lung cancer , pancreatic cancer , solid tumor . Conditions responsive paclitaxel non-hematological solid tumor malignancy good clinical candidate treatment ABI-007 .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>1 . Signed date informed consent , willing able comply protocol requirement , 2 . Histologically cytologically proven adenocarcinoma pancreas , 3 . Metastatic disease confirm ( stage IV ) , 4 . No prior therapy metastatic disease ( case previous adjuvant therapy , interval end chemotherapy relapse must &gt; 12 month ) , 5 . At least one measurable evaluable lesion assess CTscan MRI ( Magnetic Resonance Imaging ) accord RECIST v1.1 guideline , 6 . Age ≥18 year , 7 . ECOG Performance status ( PS ) 02 , 8 . Hematological status : neutrophil ( ANC ) &gt; 1.5x109/L ; platelet &gt; 100x109/L ; haemoglobin ≥9g/dL , 9 . Adequate renal function : serum creatinine level &lt; 150µM , 10 . Adequate liver function : AST ( SGOT ) ALT ( SGPT ) ≤2.5xULN ( ≤5xULN case liver metastasis ) 11 . Total bilirubin ≤1.5 x ULN , albumin ≥25g/L 12 . Baseline evaluation perform randomization : clinical blood evaluation 2 week ( 14 day ) prior randomization , tumor assessment ( CTscan MRI , evaluation nonmeasurable lesion ) 3 week ( 21 day ) prior randomization , 13 . Female patient must surgically sterile , postmenopausal , must commit use reliable appropriate method contraception study least six month end study treatment ( applicable ) . All female patient reproductive potential must negative pregnancy test ( β HCG ) within 72 hour prior start ABI007 treatment . Breastfeeding allow . Male patient must agree use effective contraception addition partner use contraceptive method well trial least six month end study treatment , 14 . Registration national health care system ( CMU include France ) . 1 . History evidence upon physical examination CNS metastasis unless adequately treat ( e.g . non irradiated CNS metastasis , seizure control standard medical therapy ) 2 . Local locally advance disease ( stage I III ) , 3 . Patient us warfarin , 4 . Uncontrolled hypercalcemia , 5 . Preexisting permanent neuropathy ( NCI grade ≥2 ) , 6 . Known dihydropyrimidine dehydrogenase ( DPD ) deficiency , 7 . Concomitant unplanned antitumor therapy ( e.g . chemotherapy , molecular target therapy , immunotherapy ) , 8 . Treatment investigational medicinal product within 28 day prior study entry , 9 . Other serious uncontrolled nonmalignant disease ( eg . active infection require systemic therapy , coronary stenting myocardial infarction stroke past 6 month ) , 10 . Known historical active infection HIV , know active infection untreated hepatitis B hepatitis C. 11 . History active interstitial lung disease ( ILD ) , 12 . Other concomitant previous malignancy , except : i/ adequately treat insitu carcinoma uterine cervix , ii/ basal squamous cell carcinoma skin , iii/ cancer complete remission &gt; 5 year , 13 . Patients know allergy excipient study drug , 14 . Concomitant administration live , attenuated virus vaccine yellow fever vaccine concomitant administration prophylactic phenytoin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Metastatic</keyword>
	<keyword>Pancreatic</keyword>
	<keyword>Cancer</keyword>
	<keyword>Pancreas</keyword>
	<keyword>GERCOR</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>LV5FU2</keyword>
	<keyword>ABI-007</keyword>
	<keyword>PACLITAXEL ALBUMIN-BOUND PARTICLES</keyword>
</DOC>